

Nectar Lifesciences Ltd.



Ref No. NLL/CS/2013- 244 & 245

Dated: 14.02.2013

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub: Compliance under Clause 41 the Listing Agreement.

Sirs,

Pursuant to Clause 41 of the Listing Agreement, please find enclosed herewith a copy of the Unaudited Financial Results for the period ended on 31st December, 2012, as approved by the Board of Directors in their meeting held on even date i.e. 14th February, 2013 and copy of Limited Review Report by Auditors.

Kindly take the same on record and oblige.

Thanking you,

Yours truly,

For NECTAR LIFESCIENCES LIMITED


Sunder Lal
Company Secretary

Encl. as above

CC:- Societe de la Bourse de Luxembourg S.A.
BP 165, L-2011 Luxembourg,
Telephone : (00352) 47 79 38-1
Fax: (00352) 47 32 98



S. No	PARTICULARS	Quarter ended 31.12.2012	Quarter ended 30.09.2012	Quarter ended 31.12.2011	9 Months ended 31.12.2012	9 Months ended 31.12.2011	Year ended 31.03.2012
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Income from Operations						
	(a) Gross Sales	38095.64	50582.52	41711.79	129091.37	93556.36	134173.78
	Less : Excise Duty	1207.10	1108.49	719.24	3373.80	2656.77	3845.02
	Net Sales	36888.54	49474.03	40992.55	125717.57	90899.59	130328.76
	(b) Other Operating Income	18.85	52.77	164.47	133.47	643.60	981.84
	Total Income from Operations (net)	36907.39	49526.80	41157.02	125851.04	91543.19	131310.60
2.	Expenses						
	(a) Cost of Materials consumed	30121.56	36940.47	27029.73	91328.65	58268.36	99060.46
	(b) Purchase of Stock in Trade	845.34	990.62	1616.37	5335.82	4387.95	6302.74
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(6041.24)	(331.98)	530.37	(4892.21)	(84.60)	(13466.91)
	(d) Employee benefits expense	1137.2	1149.93	1221.82	3362.19	3696.56	4765.86
	(e) Depreciation and amortisation expense	1922.39	1919.59	1663.36	5634.58	4497.27	6072.94
	(f) Other expenses	3649.36	3678.50	3288.82	10384.16	7593.74	11018.76
	Total Expenses	31634.61	44347.13	35350.47	111153.19	78359.28	113753.85
3.	Profit from Operations before Other Income, finance costs and exceptional Items (1-2)	5272.78	5179.67	5806.55	14697.85	13183.91	17556.75
4.	Other Income	412.72	412.71	412.18	1237.42	862.83	1289.40
5.	Profit before finance costs and exceptional Items (3+4)	5685.50	5592.38	6218.73	15935.27	14046.74	18846.15
6.	Finance costs	2817.41	2767.91	2542.82	8078.09	6610.95	10299.51
7.	Profit after finance costs but before exceptional Items (5-6)	2868.09	2824.47	3675.91	7857.18	7435.79	8546.64
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	2868.09	2824.47	3675.91	7857.18	7435.79	8546.64
10.	Tax Expense	723.46	569.53	436.94	1854.84	944.54	1221.64
11.	Net Profit from ordinary activities after tax (9-10)	2144.63	2254.94	3238.97	6002.34	6491.25	7325.00
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	2144.63	2254.94	3238.97	6002.34	6491.25	7325.00
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61
15.	Reserves excluding Revaluation Reserves	-	-	-	-	-	76,212.05
16.i	Earnings per Share (EPS) (before extraordinary items)						
	a) Basic	0.96	1.01	1.44	2.68	2.89	3.27
	b) Diluted	0.96	1.01	1.44	2.68	2.89	3.27
16.ii	Earnings per Share (EPS) (after extraordinary items)						
	a) Basic	0.96	1.01	1.44	2.68	2.89	3.27
	b) Diluted	0.96	1.01	1.44	2.68	2.89	3.27

Part II Select Information for the Quarter and Nine month ended 31.12.2012

A	Particulars of shareholding						
1.	Public Shareholding						
	- Number of Shares	12,47,92,970	12,47,92,970	12,48,56,970	12,47,92,970	12,48,56,970	12,47,92,970
	- Percentage of Shareholding	55.65	55.65	55.67	55.65	55.67	55.65
2.	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	9,94,68,000	9,94,68,000	9,94,04,000	9,94,68,000	9,94,04,000	9,94,68,000
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	44.35	44.35	44.33	44.35	44.33	44.35
B	Investor Complaints						
	Pending at the beginning of Quarter						
	Received During the Quarter				8		
	Disposed Off During the Quarter				8		
	Pending at the end of Quarter						

Notes:

- The above financial results were reviewed by Audit Committee on 13.02.2013 and approved by the Board in its meeting held on even date i.e. 14.02.2013 and further limited reviewed by the Statutory Auditors of the Company.
- The company is exclusively in the pharmaceutical business segment.
- Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- The above financial results are on stand alone basis.

By Order of the Board of Directors
of Nectar Lifesciences Limited
sd/-
(Sanjiv Goyal)
Chairman & Managing Director

Certified to be true copy
For NECTAR LIFESCIENCES LIMITED

Sunder Lal
Company Secretary

Dated: 14.02.2013
Place: Chandigarh



DATTA SINGLA & CO.

CHARTERED ACCOUNTANTS


To Whom It May Concern

We have reviewed the accompanying statement of unaudited financial results of Nectar Lifesciences Limited for the quarter ended December 31, 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Datta Singla & Company
Chartered Accountants


Partner's Name: YOGESH MOUSA
Membership No.: 089813

Place: Chandigarh

Date: 14-02-2013

Certified to be true copy

For NECTAR LIFESCIENCES LIMITED


Sunder Lal
Company Secretary